COMMUNIQUÉS West-GlobeNewswire

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

12/11/2024 - 22:21

Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC Announced agreement with Roche to [...]

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

12/11/2024 - 22:26

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 [...]

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

12/11/2024 - 22:30

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the Company’s annual and [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12/11/2024 - 22:30

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

12/11/2024 - 22:30

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), [...]

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

12/11/2024 - 22:45

BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today [...]

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

12/11/2024 - 22:54

OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion ( [...]

STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group

11/11/2024 - 14:15

HORSHAM, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]

Inozyme Pharma to Present at Upcoming Investor Conferences

11/11/2024 - 14:30

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]

Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

11/11/2024 - 14:30

CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing Dose-dependent exposure was observed with evidence of robust brain penetration Data supports potential advancement into [...]

NEXGEL to Report Third Quarter 2024 Financial Results on November 13th

11/11/2024 - 15:00

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, [...]

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

11/11/2024 - 15:05

MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]

AMN Healthcare Commits to Science-Based Targets, Leading the Charge Towards a Sustainable Future

11/11/2024 - 15:06

DALLAS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare, the leader and innovator in total talent solutions for healthcare organizations, announces it has approved near and long-term science-based emissions reduction [...]

Johnson & Johnson dépose des demandes d’autorisation aux États-Unis et dans l’Union européenne du DARZALEX FASPRO®/DARZALEX® (daratumumab) en tant que monothérapie sous-cutanée destinée au traitement du myélome multiple indolent à haut risq

11/11/2024 - 15:46

En cas d’obtention de l’autorisation, le daratumumab deviendra la première option thérapeutique pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, [...]

ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024

11/11/2024 - 15:52

GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be [...]

New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines

11/11/2024 - 15:52

Access to Life-Saving Drugs can be Delayed or Denied when Regulators and Health Plans Rely on Outdated Cost-Effectiveness Analysis (CEA) Methodology WASHINGTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- As policymakers [...]

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024

11/11/2024 - 16:07

MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for [...]

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

11/11/2024 - 17:00

Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, [...]

QC Kinetix National Medical Director Dr. Mitchell Sheinkop is the Keynote Speaker at the International Conference on Stem Cells and Regenerative Medicine

11/11/2024 - 17:26

Dr. Sheinkop will advise physicians involved in Regenerative Medicine worldwide on “Translating the Potential of OrthoBiologics Treatment into Clinical Practice” Dr. Mitchell Sheinkop CHARLOTTE, N.C., Nov. 11, 2024 ( [...]